Hepatocellular carcinoma: Advances in systemic therapies.
Wu TK, Hui RW, Mak LY, Fung J, Seto WK, Yuen MF.
F1000Res. 2024 May 7;13:104. doi: 10.12688/f1000research.145493.2. eCollection 2024.
Lowe Syndrome.
Lewis RA, Nussbaum RL, Brewer ED.
2001 Jul 24 [updated 2019 Apr 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Gill AJ.
Mod Pathol. 2021 Jul;34(7):1392-1424. doi: 10.1038/s41379-021-00779-w. Epub 2021 Mar 4.
Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology.
Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian-Cheff A, Geng Y, Herrmann SM.
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):1061-1072. doi: 10.2215/CJN.0000000000000508. Epub 2024 Jun 7.
A case of primary renal oncocytic tumor: Chromophobe renal cell carcinoma or oncocytoma?
Matsui K, Uchida K, Kanai M, Asakawa K, Usui M, Murata T.
IJU Case Rep. 2022 Sep 16;6(1):18-21. doi: 10.1002/iju5.12535. eCollection 2023 Jan.
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS.
JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.
Transitional B cell cytokines risk stratify early borderline rejection after renal transplantation.
Cherukuri A, Abou-Daya KI, Chowdhury R, Mehta RB, Hariharan S, Randhawa P, Rothstein DM.
Kidney Int. 2023 Apr;103(4):749-761. doi: 10.1016/j.kint.2022.10.026. Epub 2022 Nov 25.
Pseudomyxoma peritonei associated with primary mucinous borderline tumor of the renal pelvicalyceal system.
Rao P, Pinheiro N Jr, Franco M, Ra S, Costa H, Manzano J, Paner GP, Silva EG, Amin MB.
Arch Pathol Lab Med. 2009 Sep;133(9):1472-6. doi: 10.5858/133.9.1472.
A transitional B-cell cytokine biomarker for risk stratifying renal transplant patients with borderline rejection.
Basu S, Dorling A, Chong AS.
Kidney Int. 2023 Apr;103(4):658-660. doi: 10.1016/j.kint.2022.12.020.
Solid renal masses: what the numbers tell us.
Kang SK, Huang WC, Pandharipande PV, Chandarana H.
AJR Am J Roentgenol. 2014 Jun;202(6):1196-206. doi: 10.2214/AJR.14.12502.
